


REMARKS

The specification has been amended in order to correct obvious typographical errors contained therein. No new matter has been added.

Claims 7-14 have been rejected under 35 USC 112, first and second paragraphs, for utilizing the word "derivative". In order to expedite the prosecution of the present application, Claim 7 has been amended to state that a high density lipoprotein and/or a peptide or protein of the sequence of apo A-I or apo A-II or a peptide or protein functionally homologous to the active portions of apo A-I or apo A-II in pharmaceutically acceptable form is administered to a human patient. Newly presented Claims 15 and 16 require that high density lipoprotein is administered to the patient. No new matter has been added. Claims 9 and 10 have been canceled as being redundant.

Since only formal rejections were made in the present application and the currently presented amendments have cured these formal rejections, it is respectfully submitted that the present application is now in condition for allowance. If the Examiner feels that there are any outstanding matters left to be resolved in the present application, he is respectfully requested to contact the undersigned in order that they may be dealt with.

Respectfully submitted,



TFC/smd

Terryence F. Chapman

FLYNN, THIEL, BOUTELL & TANIS, P.C. 2026 Rambling Road Kalamazoo, MI 49008-1631 Phone: (269) 381-1156 Fax: (269) 381-5465	Dale H. Thiel David G. Boutell Ronald J. Tanis Terryence F. Chapman Mark L. Maki Liane L. Churney Brian R. Tumm Steven R. Thiel Donald J. Wallace Sidney B. Williams, Jr.	Reg. No. 24 323 Reg. No. 25 072 Reg. No. 22 724 Reg. No. 32 549 Reg. No. 36 589 Reg. No. 40 694 Reg. No. 36 328 Reg. No. 53 685 Reg. No. 43 977 Reg. No. 24 949
--	--	--

Encl: Postal Card

136.05/04